Progress in the fight against the pandemic is being made rapidly with updates coming from around the world. Here, find up to the minute news items and resources for members of the media.




AstraZeneca is responding to the COVID-19 global pandemic in a manner consistent with our values: to follow the science, put patients first and do the right thing.

We continue to support the global effort to fight the pandemic, collaborating with scientists, governments and multilateral organisations, to accelerate efforts to advance the development of potential medicines to prevent or treat the infection, to boost diagnostic testing and to help protect healthcare workers on the frontline.

We joined forces with the University of Oxford1 to bring together its world-class expertise in vaccinology with our global development and manufacturing capabilities. We have accelerated development and rapidly mobilised a global supply chain to supply the potential vaccine broadly and equitably across the globe, when approvals are granted, and at no profit during the pandemic2.

Complementing our vaccines approach, we also quickly mobilised research efforts to advance the development of a coronavirus-neutralising long-acting antibody combination (LAAB) for the potential prevention and treatment of COVID-19. 

We continue to ensure the supply and quality of our medicines to patients and to safeguard the health and wellbeing of all our employees. We have also provided our expertise in science and technology to international health authorities, such as the World Health Organization (WHO) and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Clinical development of the vaccine is ongoing, assessing efficacy, safety and immune responses in up to 60,000 participants globally across a broad age range and diverse racial, ethnic and geographic groups.

Looking at all the data from clinical trials and real world evidence, our vaccine is well tolerated3 and highly effective4 against COVID-19 across all disease severities with similar efficacy across all demographics and in particular all adult age groups, including in individuals aged 65 years and over.

The vaccine has been shown to:

...reduce severe disease and hospitalisation from COVID-19 infection with 100% efficacy in clinical trials5 in up to 60,000 participants, and by more than 80% from real world evidence in tens of millions of people effective against all severities of symptomatic COVID-19 across ethnicities and age, with ~80% efficacy in clinical trials and a trend of increased efficacy with a longer than 4 week dosing interval.

Pre-clinical and clinical studies have been conducted to evaluate the effectiveness of Covid-19 Vaccine AstraZeneca against three global variants of concern.

Clinical studies 6 confirmed the vaccine is effective against the B.1.1.7 variant, with comparable efficacy to the predominant global strain

Pre-clinical studies 7 showed antibodies from vaccinated individuals were able to neutralise the P.1. variant to a similar extent as the Victoria strain and B.1.1.7 variant, indicating similar levels of protection could be achieved against this variant in the real world setting.

Analysis from the small Phase I/II COV005 trial in South Africa 8was unable to conclude that the vaccine protects against severe disease from the B.1.351variant due to the young average age of the trial participants. Pre-clinical studies have demonstrated the vaccine’s effectiveness against the B.1.351 variant, showing lower respiratory tract protection and viral clearance in animal models9. Further clinical analysis is planned to confirm the effectiveness against severe disease from this variant.

The World Health Organisation’s Strategic Advisory Group of Experts on Immunization (SAGE) has recommendedCOVID-19 Vaccine AstraZeneca in countries where new variants, including B.1.351 are prevalent.

The vaccine has been granted a conditional marketing authorisation or emergency use in more than 70 countries across six continents, and with the recent Emergency Use Listing granted by the World Health Organization this accelerates the pathway to access in up to 142 countries through the COVAX Facility.

AstraZeneca are committed to broad and equitable supply of the vaccine at no profit during the period of the pandemic. We continue to identify and forge partnerships to develop a number of supply chains around the world.

Clinical trials are being initiated to study vaccine effectiveness across different populations, for example paediatrics and pregnant women and investigating interchangeability across different vaccine platforms, known as heterologous boosting.

We are deeply committed to the safety of our participants and to maintaining the highest standards of conduct across all our clinical trials.

Our current focus is delivering on our substantial global commitments to governments and international health organizations, as quickly as possible to help end the pandemic; as such there is currently no private sector supply, sale or distribution of the vaccine.

If someone offers private vaccines, it is likely counterfeit, so should be refused and reported to local health authorities.

1. AstraZeneca PLC. AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine. Available at: [Last Accessed: Jan 2021]

2. AstraZeneca PLC. AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit. Available at: [Last accessed: Sept 2020]

3. Voysey M, Clemens SAC, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. [Online]. Available at: [Last accessed: 21 Mar 2021]

4. AstraZeneca PLC. COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials. [Online]. Available at: [Last accessed: 21 Mar 2021]

5. Voysey M, Clemens SAC, Madhi SA, et al; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397 (10269): 99-111.

6. Emary KRW, Golubchik T, Aley PK, et al; Consortium, COVID-19 Genomics UK (COG-UK) Group; Oxford COVID Vaccine Trial. Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7). [Online] Available at SSRN: or [Last accessed: 21 Mar 2021]

7. Dejnirattisai, W., Zhou, D., Supasa, P., et al. Antibody evasion by the Brazilian P.1. strain of SARS-CoV-2. bioRxiv [Online as pre-print]. Available at: [Last accessed: 21 March 2021]

8. Madhi, S., Baillie, V., Cutland, C. et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. [Online] Available at [Last accessed: 21 March 2021]

9. Fischer, R.J., van Doremalen, N., Adney, D.R. et al.; ChAdOx1 nCoV-19 (AZD1222) protects hamsters against SARS-CoV-2 B.1.351 and B.1.1.7 disease. bioRxiV [Online as pre-print]. Available at: [Last accessed: 17 March 2021]

10. AstraZeneca PLC. Advancing our discovery of novel coronavirus-neutralising antibodies against COVID-19. [Online] Available at: [Last accessed 21 March 2021]

11. Zost SJ et al. Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals. Nature. 2020. DOI: 10.1038/s41586-020-2548-6. Preprint available online at: [Last accessed 21 March 2021]

Media contacts

Email the Global Media Relations team at

Gonzalo Viña
Head of Global Media Relations
+44 (0)1223 344 800

Kim Blomley
Director Global Media Relations
+44 (0)1223 344 800

Matthew Kent
Director Global Media Relations
+44 (0)1223 344 800

Angela Fiorin
Director Global Media Relations
+44 (0)1223 344 800

Fiona Cookson
Director Global Media Relations
+44 (0)1223 344 800

Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+44 (0)1223 344 800